The US FDA has cleared the IND application of the company’s BTX-9341 to initiate the P-I clinical evaluation for treating breast cancer, in H2’24
The P-I dose escalation study of BTX-9341 monotx. and in combination with fulvestrant aims at assessing its safety, biological activity and preliminary efficacy for treating HR+/HER2- breast cancer resistant to CDK4/6 inhibitor therapies
BTX-9341 (oral) is a FIC, CDK4 and CDK6 degrader that inhibited Cyclin E and CDK2 transcription by potent and selectively degrading CDK4 and CDK6, leading to superior in vivo effectiveness in breast cancer xenografts
Ref: Biotheryx | Image: Biotheryx
Related News:- Biotheryx Entered into a Research Collaboration and License agreement with Incyte to Discover and Develop Targeted Protein Degraders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
